606 related articles for article (PubMed ID: 16002667)
1. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
2. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
[TBL] [Abstract][Full Text] [Related]
3. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin.
Hayakawa Y; Kelly JM; Westwood JA; Darcy PK; Diefenbach A; Raulet D; Smyth MJ
J Immunol; 2002 Nov; 169(10):5377-81. PubMed ID: 12421908
[TBL] [Abstract][Full Text] [Related]
4. Activation of V gamma 9V delta 2 T cells by NKG2D.
Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
[TBL] [Abstract][Full Text] [Related]
5. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis.
Saikali P; Antel JP; Newcombe J; Chen Z; Freedman M; Blain M; Cayrol R; Prat A; Hall JA; Arbour N
J Neurosci; 2007 Jan; 27(5):1220-8. PubMed ID: 17267578
[TBL] [Abstract][Full Text] [Related]
6. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells.
Burgess SJ; Marusina AI; Pathmanathan I; Borrego F; Coligan JE
J Immunol; 2006 Feb; 176(3):1490-7. PubMed ID: 16424177
[TBL] [Abstract][Full Text] [Related]
7. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway.
Westwood JA; Kelly JM; Tanner JE; Kershaw MH; Smyth MJ; Hayakawa Y
J Immunol; 2004 Jan; 172(2):757-61. PubMed ID: 14707044
[TBL] [Abstract][Full Text] [Related]
8. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein.
Wu J; Chalupny NJ; Manley TJ; Riddell SR; Cosman D; Spies T
J Immunol; 2003 Apr; 170(8):4196-200. PubMed ID: 12682252
[TBL] [Abstract][Full Text] [Related]
9. Blastocyst MHC, a putative murine homologue of HLA-G, protects TAP-deficient tumor cells from natural killer cell-mediated rejection in vivo.
Tajima A; Tanaka T; Ebata T; Takeda K; Kawasaki A; Kelly JM; Darcy PK; Vance RE; Raulet DH; Kinoshita K; Okumura K; Smyth MJ; Yagita H
J Immunol; 2003 Aug; 171(4):1715-21. PubMed ID: 12902470
[TBL] [Abstract][Full Text] [Related]
10. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer S; Groh V; Wu J; Steinle A; Phillips JH; Lanier LL; Spies T
Science; 1999 Jul; 285(5428):727-9. PubMed ID: 10426993
[TBL] [Abstract][Full Text] [Related]
11. Potential role of NKG2D/MHC class I-related chain A interaction in intrathymic maturation of single-positive CD8 T cells.
Hüe S; Monteiro RC; Berrih-Aknin S; Caillat-Zucman S
J Immunol; 2003 Aug; 171(4):1909-17. PubMed ID: 12902493
[TBL] [Abstract][Full Text] [Related]
12. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.
Girart MV; Fuertes MB; Domaica CI; Rossi LE; Zwirner NW
J Immunol; 2007 Sep; 179(6):3472-9. PubMed ID: 17804388
[TBL] [Abstract][Full Text] [Related]
13. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
14. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.
Takaki R; Hayakawa Y; Nelson A; Sivakumar PV; Hughes S; Smyth MJ; Lanier LL
J Immunol; 2005 Aug; 175(4):2167-73. PubMed ID: 16081783
[TBL] [Abstract][Full Text] [Related]
15. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
16. IL-2-activated CD8+CD44high cells express both adaptive and innate immune system receptors and demonstrate specificity for syngeneic tumor cells.
Dhanji S; Teh HS
J Immunol; 2003 Oct; 171(7):3442-50. PubMed ID: 14500639
[TBL] [Abstract][Full Text] [Related]
17. Nonconventional CD8+ T cell responses to Listeria infection in mice lacking MHC class Ia and H2-M3.
Cho H; Choi HJ; Xu H; Felio K; Wang CR
J Immunol; 2011 Jan; 186(1):489-98. PubMed ID: 21098224
[TBL] [Abstract][Full Text] [Related]
18. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
19. The role of the NKG2D immunoreceptor in immune cell activation and natural killing.
Jamieson AM; Diefenbach A; McMahon CW; Xiong N; Carlyle JR; Raulet DH
Immunity; 2002 Jul; 17(1):19-29. PubMed ID: 12150888
[TBL] [Abstract][Full Text] [Related]
20. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.
Oppenheim DE; Roberts SJ; Clarke SL; Filler R; Lewis JM; Tigelaar RE; Girardi M; Hayday AC
Nat Immunol; 2005 Sep; 6(9):928-37. PubMed ID: 16116470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
